NASDAQ : CRBP
Corbus Pharmaceuticals Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 81.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 81.62M |
| Enterprise Value | -32.06M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.34M |
| Shares Outstanding | 19.34M |
| Shares Change (YoY) | +37.35% |
| Shares Change (QoQ) | +3.75% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 43.86% |
| Float | 13.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 73.46 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.71 |
| Quick Ratio | 5.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -95.58% |
| Return on Assets (ROA) | -53.00% |
| Return on Invested Capital (ROIC) | -60.74% |
| Return on Capital Employed (ROCE) | -101.30% |
| Weighted Average Cost of Capital (WACC) | 18.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.83M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.79 |
| 52-Week Price Change | -74.97% |
| 50-Day Moving Average | 7.17 |
| 200-Day Moving Average | 8.62 |
| Relative Strength Index (RSI) | 25.58 |
| Average Volume (20 Days) | 971,654 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.71M |
| Short Previous Month | 3.05M |
| Short % of Shares Out | 14.03% |
| Short % of Float | 20.49% |
| Short Ratio (days to cover) | 2.68 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -90.26M |
| Operating Income | -106.88M |
| Pretax Income | -101.90M |
| Net Income | -101.90M |
| EBITDA | -106.68M |
| EBIT | -106.88M |
| Earnings Per Share (EPS) | -$6.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 117.94M |
| Total Debt | 4.26M |
| Net Cash | 113.68M |
| Net Cash Per Share | $5.88 |
| Equity (Book Value) | 102.24M |
| Book Value Per Share | 5.48 |
| Working Capital | 101.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -86.67M |
| Capital Expenditures | -19,000 |
| Depreciation & Amortization | 199,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -86.69M |
| FCF Per Share | -$4.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -37.35% |
| Shareholder Yield | n/a |
| Earnings Yield | -144.29% |
| FCF Yield | -106.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $34.89 |
| Price Target Difference | 726.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |